Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Madison, Wisconsin 53792


Purpose:

Two investigational chemical tracers, 62Cu-ethylglyoxal bis(thiosemicarbazone) (62Cu-ETS) and 15O-water, will be used in this study to look at how blood moves through the kidneys. The purpose of the study is to see if 62Cu-ETS is effective in showing the blood supply to the kidneys compared to 15O-water. The tracer mixes with the blood and moves through the body. Using positron emission tomography (PET scan) the researchers can see the tracer and can learn more about how the blood moves through the kidneys. The study invites participants who are healthy, without any heart or kidney disease, patients who have kidney disease that require dialysis, and patients who may have a blockage in one of the arteries supplying blood to the kidneys.


Criteria:

Arm 1. Inclusion Criteria: - males and females, age 18-40 years - willingness to provide written informed consent Exclusion Criteria: - history of coronary artery disease (CAD) - history of renal disease - risk factors for cardiac disease, renal disease, or atherosclerosis, including diabetes mellitus, hypertension, tobacco abuse, hyperlipidemia, family history of CAD or chronic renal failure - history of liver disease or other significant disease - pregnant females Arm 2. Inclusion Criteria: - males and females, age > 18 years - active hemodialysis or peritoneal dialysis for at least six months - any etiology of chronic renal failure except active glomerular nephritis - presence of two kidneys - willingness to provide written informed consent Exclusion Criteria: - decompensated heart failure (subjects must be on stable medical therapy for one month) - any previous renal transplant (subjects may be on renal transplant waiting list) - history of liver disease - pregnant females Arm 3. Inclusion Criteria: - males and females, age > 18 years - documented evidence of renal artery stenosis equivalent to a 75% stenosis by one of the following clinical tests: MRA, Doppler, Renal Angiogram, Abnormal captopril renal scan - evidence of renal insufficiency with serum creatinine >= 1.3 mg/dL - presence of two kidneys - willingness to provide written informed consent Exclusion Criteria: - revascularization of stenotic renal artery - decompensated heart failure (subjects must be on stable medical therapy for one month) - any previous renal transplant (subjects may be on renal transplant waiting list) - history of liver disease - pregnant females


NCT ID:

NCT00714142


Primary Contact:

Principal Investigator
Jeffrey L Lacy, PhD
Proportional Technologies, Inc.


Backup Contact:

N/A


Location Contact:

Madison, Wisconsin 53792
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 19, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.